File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Serum soluble interleukin 2 receptor in hyperthyroid Graves' disease and effect of carbimazole therapy

TitleSerum soluble interleukin 2 receptor in hyperthyroid Graves' disease and effect of carbimazole therapy
Authors
Issue Date1990
PublisherWiley-Blackwell Publishing Ltd.. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0300-0664
Citation
Clinical Endocrinology, 1990, v. 33 n. 3, p. 317-321 How to Cite?
AbstractTo study the activation of T lymphocytes in hyperthyroid Graves' disease, the serum concentrations of soluble interleukin 2 receptors (sIL2R) were determined during active thyrotoxicosis and following the return to a euthyroid state with carbimazole therapy. Serum sIL2R was measured by an enzyme linked immunoassay. The mean ± SD serum sIL2R concentration during untreated hyperthyroidism was elevated as compared with controls (919.1 ± 523.4 vs 374.2 ± 189.4 U/ml, P < 0.005). However, after carbimazole therapy the serum sIL2R in euthyroid patients fell to 377.9 ± 90.3 U/ml, which did not differ from healthy controls. Serum sIL2R correlated significantly with the serum free T3 only during hyperthyroidism (r = 0.678, P < 0.01). Our study suggests that in vivo measurement of serum sIL2R released from activated T lymphocytes is a useful immunological indicator of disease activity.
Persistent Identifierhttp://hdl.handle.net/10722/161813
ISSN
2015 Impact Factor: 3.487
2015 SCImago Journal Rankings: 1.314
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChow, CCen_HK
dc.contributor.authorLai, KNen_HK
dc.contributor.authorLeung, JCKen_HK
dc.contributor.authorChang, JCNen_HK
dc.contributor.authorCockram, CSen_HK
dc.date.accessioned2012-09-05T05:15:14Z-
dc.date.available2012-09-05T05:15:14Z-
dc.date.issued1990en_HK
dc.identifier.citationClinical Endocrinology, 1990, v. 33 n. 3, p. 317-321en_HK
dc.identifier.issn0300-0664en_HK
dc.identifier.urihttp://hdl.handle.net/10722/161813-
dc.description.abstractTo study the activation of T lymphocytes in hyperthyroid Graves' disease, the serum concentrations of soluble interleukin 2 receptors (sIL2R) were determined during active thyrotoxicosis and following the return to a euthyroid state with carbimazole therapy. Serum sIL2R was measured by an enzyme linked immunoassay. The mean ± SD serum sIL2R concentration during untreated hyperthyroidism was elevated as compared with controls (919.1 ± 523.4 vs 374.2 ± 189.4 U/ml, P < 0.005). However, after carbimazole therapy the serum sIL2R in euthyroid patients fell to 377.9 ± 90.3 U/ml, which did not differ from healthy controls. Serum sIL2R correlated significantly with the serum free T3 only during hyperthyroidism (r = 0.678, P < 0.01). Our study suggests that in vivo measurement of serum sIL2R released from activated T lymphocytes is a useful immunological indicator of disease activity.en_HK
dc.languageengen_US
dc.publisherWiley-Blackwell Publishing Ltd.. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0300-0664en_HK
dc.relation.ispartofClinical Endocrinologyen_HK
dc.subject.meshAdulten_US
dc.subject.meshCarbimazole - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshGraves Disease - Blood - Drug Therapyen_US
dc.subject.meshHumansen_US
dc.subject.meshLymphocyte Activation - Drug Effectsen_US
dc.subject.meshMaleen_US
dc.subject.meshReceptors, Interleukin-2 - Analysisen_US
dc.subject.meshT-Lymphocytes - Drug Effectsen_US
dc.subject.meshTriiodothyronine - Blooden_US
dc.titleSerum soluble interleukin 2 receptor in hyperthyroid Graves' disease and effect of carbimazole therapyen_HK
dc.typeArticleen_HK
dc.identifier.emailLai, KN: knlai@hku.hken_HK
dc.identifier.emailLeung, JCK: jckleung@hku.hken_HK
dc.identifier.authorityLai, KN=rp00324en_HK
dc.identifier.authorityLeung, JCK=rp00448en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1365-2265.1990.tb00496.x-
dc.identifier.pmid2253407-
dc.identifier.scopuseid_2-s2.0-0024990927en_HK
dc.identifier.volume33en_HK
dc.identifier.issue3en_HK
dc.identifier.spage317en_HK
dc.identifier.epage321en_HK
dc.identifier.isiWOS:A1990DV19000001-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridChow, CC=8252323700en_HK
dc.identifier.scopusauthoridLai, KN=7402135706en_HK
dc.identifier.scopusauthoridLeung, JCK=7202180349en_HK
dc.identifier.scopusauthoridChang, JCN=7601547759en_HK
dc.identifier.scopusauthoridCockram, CS=7006379262en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats